Search

Your search keyword '"D. Haritz"' showing total 2 results
Start Over Author "D. Haritz" Topic chemistry
2 results on '"D. Haritz"'

1. Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

Author

D Haritz, Detlef Gabel, D Preusse, Crister Ceberg, F Grochulla, Heinz Fankhauser, Klaus Haselsberger, H D Peters, and U Klotz

Subjects
Adult, Male, medicine.medical_treatment, chemistry.chemical_element, Phases of clinical research, Boron Neutron Capture Therapy, Borohydrides, Pharmacology, Pharmacokinetics, Glioma, medicine, Humans, Boron, Aged, Aged, 80 and over, Chemotherapy, business.industry, Brain Neoplasms, Middle Aged, medicine.disease, Radiation therapy, Clinical trial, Neutron capture, chemistry, Surgery, Female, Neurology (clinical), business, Nuclear medicine
Abstract

The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

Published
1997

2. Clinical Investigations in Boron Neutron Capture Therapy (BNCT): Pharmacokinetic, Biodistribution, and Toxicity of Na2B12H11SH (BSH) in Patients with Malignant Glioma

Author

K. Piscol, H. Klein, Detlef Gabel, and D. Haritz

Subjects
inorganic chemicals, Biodistribution, Chemistry, Radiochemistry, technology, industry, and agriculture, chemistry.chemical_element, Neutron radiation, medicine.disease, Neutron capture, Pharmacokinetics, Glioma, Toxicity, medicine, In patient, Boron
Abstract

One of the goals of the European Collaboration on Boron Neutron Capture Therapy is to treat malignant gliomas (WHO grade III–IV), using Na2B12H11SH (BSH) as boron carrier. To treat these tumors with boron neutron capture therapy, it is necessary to accumulate sufficient amounts of boron in the tumor prior to irradiation and at the same time ensure that healthy tissue unavoidably present in the neutron beam contains a minimal amount of boron.

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results